MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Mirati Therapeutics Inc

Closed

SectorHealthcare

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-0.05% downside

Mirati Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Apr 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Alphabet, Intel, AppFolio

24 Apr 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 Apr 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 Apr 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 Apr 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 Apr 2025, 23:13 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 Apr 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 Apr 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 Apr 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 Apr 2025, 22:51 UTC

Top News
Acquisitions, Mergers, Takeovers

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 Apr 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 Apr 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 Apr 2025, 22:38 UTC

Market Talk
Earnings

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 Apr 2025, 22:24 UTC

Earnings

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 Apr 2025, 22:24 UTC

Earnings

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 Apr 2025, 22:24 UTC

Market Talk
Earnings

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 Apr 2025, 22:23 UTC

Earnings

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 Apr 2025, 22:11 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

24 Apr 2025, 22:11 UTC

Market Talk
Earnings

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 Apr 2025, 22:09 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 Apr 2025, 22:00 UTC

Market Talk
Earnings

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 Apr 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 Apr 2025, 21:24 UTC

Top News
Earnings

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 Apr 2025, 21:24 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 Apr 2025, 21:23 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 Apr 2025, 21:04 UTC

Earnings

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 Apr 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 Apr 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 Apr 2025, 21:02 UTC

Earnings

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Comparison

Price change

Mirati Therapeutics Inc Forecast

Price Target

By TipRanks

-0.05% downside

12 Months Forecast

Average 58.67 USD  -0.05%

High 59 USD

Low 58 USD

Based on 5 Wall Street analysts offering 12 month price targets forMirati Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

0

Buy

5

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.